EUVIMEDEUVIMED entdecken
Crossref

Pregnancy outcomes of GLP-1 exposure in the first trimester

Laura Dearden, Susan Elizabeth Ozanne

Apollo (University of Cambridge) · 07.09.2026

DOI: 10.17863/cam.134097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apollo (University of Cambridge), erschienen am 07.09.2026. Verfasst von Laura Dearden und 1 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists (GLP1-RAs), including semaglutide and dual incretin agonist tirzepatide, are now being obtained privately by people with or without pre-existing diabetes in the UK and elsewhere for weight management. In England, women of reproductive age account for roughly two in five of the 1.4 million people living with a BMI ≥ 40 kg/m2, suggesting they may be primary users of new weight loss drugs (1-3).

Schlagwörter

GLP-1 receptor agonistssemaglutidetirzepatidefirst trimester exposurepregnancy outcomesanti-obesity drugsobesityprenatal drug exposurepregestational diabetes

Zitieren

APA

Dearden, L., & Ozanne, S. E. (2026). Pregnancy outcomes of GLP-1 exposure in the first trimester. Apollo (University of Cambridge). https://doi.org/10.17863/cam.134097

Vancouver

Dearden L, Ozanne SE. Pregnancy outcomes of GLP-1 exposure in the first trimester. Apollo (University of Cambridge). 2026. doi:10.17863/cam.134097

BibTeX
@article{Dearden2026,
  author = {Dearden, Laura and Ozanne, Susan Elizabeth},
  title = {Pregnancy outcomes of GLP-1 exposure in the first trimester},
  journal = {Apollo (University of Cambridge)},
  year = {2026},
  doi = {10.17863/cam.134097}
}
Kostenlos starten →